In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two ...

With the FDA approval of tab-cel, the product will be transitioned to Pierre Fabre, repositioning Atara as a fully focused allogeneic CAR-T company with multiple near-term data milestones for its ...

Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

A couple of months after Thousand Oaks-based Atara Biotherapeutics announced it would be laying off roughly 80 employees, the company confirmed nearly half of those jobs are coming from its Ventura ...

In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...

President and Chief Executive Officer of Atara. "With the focus on future EBVALLO value paramount, the Company has made the difficult decision to pause development of its allogeneic CAR-T cell ...

Atara Biotherapeutics currently has a consensus ... as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431 ...

Meanwhile, CAR T-cell therapy can eliminate B cells in those ... Konig reports consulting fees from Allogene, ArgenX, Atara Biotherapeutics, Revel Pharmaceuticals and Sanofi, and teaching and ...

THOUSAND OAKS, Calif., February 07, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...